Equities

Shaanxi Kanghui Pharmaceutical Co Ltd

603139:SHH

Shaanxi Kanghui Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)13.91
  • Today's Change-0.05 / -0.36%
  • Shares traded960.00k
  • 1 Year change-17.25%
  • Beta0.8472
Data delayed at least 15 minutes, as of May 31 2024 08:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. is principally engaged in research and development, manufacture and sales of Chinese patent medicines. The Company's main products include Kun Fu Kang capsules (tablets), Fufang Shuanghua tablets, Xiaoyin granules, Fuguigutong capsules, Zhiyao Xiaoke capsules and Fufang Qingdai perfusates. The Company distributes its products just within China domestic market.

  • Revenue in CNY (TTM)588.60m
  • Net income in CNY-70.10m
  • Incorporated2009
  • Employees828.00
  • Location
    Shaanxi Kanghui Pharmaceutical Co LtdNo. 36 Yanzhi Road, Qindu DistrictXIANYANG 712000ChinaCHN
  • Phone+86 2 933347561
  • Fax+86 2 933347561
  • Websitehttp://www.sxkh.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hangzhou Tianmushan Phrmtcl ntrprs C Ltd137.86m-38.94m988.84m380.00--36.07--7.17-0.3198-0.31981.130.22510.46192.303.90362,781.80-13.21-6.93-54.44-18.9221.1633.95-28.59-16.420.5282-4.370.6609--11.82-19.4243.35---24.89--
AVE Science & Technology Co Ltd206.22m24.46m1.07bn492.0043.842.17--5.200.35970.35973.037.280.37952.0433.65419,148.404.507.214.928.1855.6958.9311.8615.485.60--0.0022.461.795.8819.81-4.62-23.68--
Shanghai Rendu Biotechnology Co Ltd170.46m18.36m1.26bn358.0068.491.31--7.380.45890.45894.2623.900.16181.122.16476,147.801.746.261.887.1780.8074.3610.7714.5411.85--0.00667.96-45.8918.85-64.60--23.48--
Shanghai Rightongene Biotechnlgy Co Ltd265.52m7.17m1.33bn501.00179.461.43--5.030.13320.13324.7516.670.25401.091.40529,970.30-0.09014.16-0.0984.4975.0270.45-0.354811.6210.43--0.02845.90-39.142.84-80.41-11.4619.65--
Shaanxi Kanghui Pharmaceutical Co Ltd676.54m-33.28m1.39bn952.00--1.46--2.05-0.3332-0.33326.779.510.34772.873.56710,646.30-3.16-0.1562-4.44-0.199126.5840.00-9.10-0.49070.6901-0.35690.366595.1536.9212.3758.52--66.95--
Shanghai Serum Bio-Technology Co Ltd192.49m37.23m1.44bn321.0038.661.32--7.480.34410.34411.7810.050.16890.92826.82599,656.403.2710.433.3210.8475.0880.5419.3432.5750.03--0.011964.939.145.67-39.54-1.6213.07--
Guangzhou LBP Medicine Scnc&Tech Co Ltd508.01m40.23m1.60bn907.0039.891.26--3.150.42920.42925.3213.610.37192.122.15560,104.201.835.101.915.5567.8375.154.9112.976.70--0.006824.42-1.9910.18-6.18-8.21-2.98--
Data as of May 31 2024. Currency figures normalised to Shaanxi Kanghui Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.37%Per cent of shares held by top holders
HolderShares% Held
Da Cheng Fund Management Co., Ltd.as of 31 Dec 2023152.50k0.28%
China Southern Asset Management Co., Ltd.as of 30 Jun 202321.30k0.04%
Nuode Asset Management Co., Ltd.as of 31 Dec 202310.20k0.02%
Fortune & Royal Asset Management Co., Ltd.as of 31 Dec 20237.00k0.01%
Maxwealth Fund Management Co., Ltd.as of 31 Dec 20233.50k0.01%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 20232.80k0.01%
Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 20230.000.00%
Lion Fund Management Co., Ltd.as of 31 Dec 20230.000.00%
Gfund Management Co., Ltd.as of 31 Dec 20230.000.00%
Western Leadbank Fund Management Co., Ltdas of 31 Dec 20230.000.00%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.